12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Copaxone glatiramer acetate regulatory update

Teva submitted a fourth Citizen's Petition to FDA that seeks to block approval of generic versions of the company's multiple sclerosis (MS) drug Copaxone glatiramer acetate. The petition, submitted June 4, requests the agency refuse to approve ANDAs for a generic version of Copaxone unless sponsors conduct...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >